Background: Epilepsy is a common serious neurological disorder. Medical histories and electroencephalogram (EEG) are not always sufficient for epilepsy diagnosis; therefore, exploring novel methods for the accurate diagnosis of epilepsy is of great importance. Recent studies indicate that Matrix metalloproteinases (MMPs) especially MMP-2 is sensitive to seizures thus; MMP-2 may be a potential biomarker for epilepsy diagnosis. Subject and method: Thirty four epileptic patients older than 2 years subjected to: Detailed medical history, general and neurological examination, routine laboratory studies, EEG , Brain magnetic resonance imaging (MRI), and serum MMP-2 level measurement . Thirty four age and sex matched healthy controls were selected and their serum MMP-2 were obtained. Results: serum MMP-2 levels were statistically significantly low in patient with idiopathic epilepsy compared to control group .Levels were less in patient with focal epilepsy than those with generalized epilepsy.Serum MMP-2 was lower in drug resistant epileptic patients and highest in newly diagnosed patients with negative correlation observed between duration of epilepsy and MMP-2 levels. Sensitivity of MMP-2 as biomarker was 85.29% with 97.06 % specificity. Conclusion: MMP-2 levels decreased in patients with epilepsy especially those with focal seizures. This tool may be a helpful diagnostic biomarker for epilepsy with a good sensitivity and specificity.
INTRODUCTION
pilepsy is one of the most common serious neurological disorders which affects about 50 million people worldwide each year [1] .with a prevalence of 5-10 cases per 1,000 [2] . The diagnosis of epilepsy is largely based on a patient's detailed, reliable medical history, and electroencephalogram (EEG) may help in the diagnosis. However, medical histories are not always sufficient, making diagnosis difficult in some cases. Therefore, exploring novel methods for the accurate diagnosis of epilepsy is of great importance [3] . Matrix metalloproteinases (MMPs) represent a family of zinc-dependent proteases with many substrates, including, cytokines, extracellular matrix components, receptors, and cell motility factors [4] .
They are the main proteolytic enzyme group involved in remodeling the extracellular matrix and maintaining the integrity of cell membrane. They play an important role in regulating organ development including muscles and nerves, maintaining normal physiology in adulthood, and they also take part in repair after injury in the nervous system [5] . Based on function and structure, MMPs can be subdivided into 5 groups: (i) collagenases (MMPs 1,8 and 13); (ii) gelatinases A and B (MMPs 2 and 9); (iii) stromelysins-1 and -2 (MMPs 3 and 10); (iv) classical MMPs 20, 12) and19 .lastly (v) membrane-type MMPs (MTMMPs 1,3,4,and 11) [6] . The most commonly expressed MMPs in the brain are MMP-2 and MMP-9 [7] .
Recently, advances have been made regarding the role of MMPs in both autoimmune and non-autoimmune neurological disorders including multiple sclerosis, myasthenia gravis, ischemic stroke, amyotrophic lateral sclerosis, migraine, Alzheimer dementia and epilepsy [8] . Metalloproteinases have been implicated in seizure-induced cell death, breakdown of the blood-brain barrier, neuroinflammation, and aberrant synaptic plasticity, all of which occur during epileptogenesis [9] , also, MMP-2 is activated in the brain in the kainic acid rat seizure model. Thus, MMP-2 may be a potential diagnostic biomarker for epilepsy in human serum. Recent studies indicate that MMP-2 and 9 is generally sensitive to seizures [10] [11] . AIM OF THIS WORK we aimed to assess serum matrix metalloproteinase -2 (MMP-2) levels in patients with idiopathic epilepsy and evaluate its role as a biomarker for diagnosis of idiopathic epilepsy. [14] . STATISTICAL ANALYSIS All data were collected, tabulated and statistically analyzed using SPSS 22.0 for windows (SPSS Inc., Chicago, IL, USA) and MedCalc 13 for windows (MedCalc Software bvba, Ostend, Belgium). Continuous variables were expressed as the mean ± SD & median (range), and the categorical variables were expressed as a number (percentage). All tests were two sided. P-value < 0.05 was considered statistically significant (S), Pvalue < 0.001 was considered highly statistically significant (HS), and p-value > 0.05 was considered statistically insignificant (NS) [15] . RESULTS our study was conducted on 34 epileptic patients; their mean age was 15 
SUBJECTS AND METHODS

DISCUSSION
We found a statistically significant difference in serum MMP-2 in between patient and control groups being higher in control group with mean of 144.99 ±14.71 ng/ml compared to 98.44±14.71 ng/ml in the case group.
These results consistent with the study of Wang et al, 2016 which concluded diminish in serum MMP-2 levels in people with epilepsy. This phenomenon concerning MMP-2 and its relation to epileptogenesis worth further investigations [16] . Previous studies noted that MMP-2 levels were not changed in animal brain tissue with epilepsy [17] [18] [19] . Hoehna et al., 2012 study was conducted on rat models and measure activity of MMP-2 and MMP-9 in rat brain influenced by pilocarpine and showed raise MMP-9 activity [17] . Li et al, 2013 [11] detected increased MMP-9 protein and activity levels in CSF from adult epilepsy patients with generalized tonic-clonic seizures compared to agematched nonepileptic individuals. Levels of MMP-9 were also increased in serum from patients after seizures.
Mizoguchi et al., 2011 [18] studied the effect of pentylenetetrazole (PTZ) induced kindled seizure on mice hippocampus which also emphasis the role of MMP-9 on seizure development with non statistically significant role proven for MMP-2. Although previous study deny any role of MMP-2 in neuronal cell death in epilepsy [20] , MMP-2 can contributes in structural remodeling in epileptogenesis since MMP-2 mRNA, protein, and activity are increased after seizures [21] [22] .These studies applied to symptomatic epilepsy while study was for idiopathic epilepsy.
Our explanation of decreased serum MMP-2 compared to high enzymatic activity in brain tissue may be due to consumption of peripheral MMP-2 and shifting intobrain to share in the process of epileptogenesis, such hypothesis worth future studies by combined serum and animal brain tissue sampling.
Our study reported that serum MMP-2 was not affected by age of both epilepsy and control groups. Serum MMP-2 has been investigated in studies of myasthenia gravis and migraine. Both reported increased serum MMP-2 levels compared to healthy controls, with no effect of age on MMP-2 levels [23] [24] [25] .On the other hand the study of Wang and colleagues [16] on 2016 show decrease in serum MMP-2 by age in both epilepsy and control groups . This discrepancy may be attributed to several factors. First, the methods used to measure MMP-2 levels differed between the studies. In the current study, we examined MMP-2 concentrations by ELISAs while the study of Wang and colleagues used Luminex technology, which has a much higher sensitivity, throughput, and efficiency than enzyme-linked immunosorbent assays (ELISAs) [26] . In addition, Wang study uses larger sample sizes and a larger age range (2-79 years) than our study [16] . Our study agreed with Wang et al, 2016 [16] who found non statistically significant sex difference in serum MMP-2 between male and female gender among patients and controls.
Serum MMP-2 in our study was found to be statistically significantly lower in patient with focal epilepsy compared to patient with generalized epilepsy. The only study, as fare as we know, concerned with such relation [15] , showed non statistically significant difference in both groups.it was done on larger sample size including wider age range with idiopathic, symptomatic and cryptogenic epilepsy patients, with a better measurement technology ( Luminex assay)
We next determined whether serum MMP-2 levels were affected by various clinical characteristics within the epilepsy group. Levels of MMP-2 were assessed in relation to disease duration, prognostic category, age at onset, and number of AED used.
Our study agreed with Wang et al, 2016 [15] , who found that MMP-2 was not affected by antiepileptic medication number.
in Multiple linear regression analysis ,we found a statistically significant negative correlation between age at onset and MMP-2 levels, serum MMP-2 is highly affected by patient prognostic category being lowest (85.93±8.27 ng/ml) in drug resistant epileptic patients and highest (119.7± 20.29 ng/ml) in the newly diagnosed patients.as shown by previous study of Wang et al., 2016 [16] . To evaluate the utility of MMP-2 levels in discriminating cases of epilepsy from normal controls, we performed ROC curve analysis, when the cut-off value of MMP-2 concentration of 111.5 ng/ml was chosen, the sensitivity and specificity for distinguishing epileptic from control subjects were 85.29 and 97.06 %, respectively, and the AUC was 0.922.
Wang and colleagues [16] came to nearly similar results as cut-off value of MMP-2 concentration was 175.40 ng/ml, the sensitivity and specificity for distinguishing epileptic from control subjects were 71.13 and 62.66%, respectively, and the AUC was 0.697.
Another study evaluated the role of MMP-2 in a variety of neurodevelopmental processes and neurological disorders, but little is known about the precise role of MMP-2 in the pathogenesis of epilepsy [27] . Another study of Mirshafiey and colleagues in 2014 [28] suggested that down regulation of MMP-2 may inhibit bloodbrain-barrier (BBB) breakdown and migration of inflammatory cells into the CNS.
Our data showed that in epileptic subjects, MMP-2 levels are lowest in epileptic patients' especially drug-resistant ones. MMP-2 is involved in the repair process following CNS injury, but MMP up regulation in neurologic conditions may be results in pathology. Therefore, the down regulation of MMP-2 may be neuroprotective in patients with epilepsy. However, the precise role of MMP-2 in the pathogenesis of epilepsy remains to be established [29] . CONCLUSION Epilepsy is a major health burden. We need reliable biomarkers for diagnosis due to a wide range of epilepsy mimics. Our study demonstrated that serum MMP-2 levels were decreased in patients with epilepsy especially those with focal seizures. This tool may be a helpful diagnostic biomarker for epilepsy with a good sensitivity and specificity.
